Cite
MLA Citation
Sean Dulloo et al.. “Comparison between 1st generation EGFR tyrosine kinase inhibitor (gefitinib) versus 2nd generation (afatinib) in EGFR-mutated non-small cell lung cancers (NSCLC) – real world experience.” Lung cancer, vol. 156, n.d., pp. S42–S43. http://access.bl.uk/ark:/81055/vdc_100131053621.0x000040